Maker of wearable Zio heart-monitoring patches and AI-based analysis services diagnosing cardiac arrhythmias.
Maker of wearable Zio heart-monitoring patches and AI-based analysis services diagnosing cardiac arrhythmias.
Is paid per monitoring service, billed to Medicare and private insurers, so reimbursement rates and coverage matter as much as the devices. Patients wear the patch for about two weeks and mail it back, and the company's analysis and clinician review produce the report.
Moat: narrow (data, brand, switching costs). Large proprietary ECG dataset trains its arrhythmia-detection algorithms, and physicians are used to its workflow.
Headquarters: San Francisco, California · Founded: 2006 · Employees: 2,400
Size iRhythm (IRTC) is a United States Health Care company (Medical Specialties) with a market value of $3.19B, the 1490th largest of 3,085 United States companies the cockpit tracks. Shares closed at $94.87 on 18 Nov 2026.
Performance Over six months the shares fell 18.9%, against +3.2% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 21.6% over the last twelve months (peer median +4.7%); the operating margin is 4.9% (peer median 9.9%).
Valuation It trades at 99.8× forward earnings against a peer median of 24.4× (2nd most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 47% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is +24 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.9 points below its cost of capital (10.8% WACC).
Credit iRhythm has 1 bond outstanding ($661M).
Short interest Short interest is 9.7% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $854M | $747M | $592M | $493M | $411M |
| Revenue growth | — | +26% | +20% | +20% | — |
| Gross profit | $617M | $527M | $408M | $332M | $282M |
| EBITDA | $68.5M | -$10.3M | -$56.7M | -$91.9M | -$67.6M |
| Net income | -$38.6M | -$44.6M | -$113M | -$123M | -$116M |
| Free cash flow | $7.38M | $34.5M | -$30.6M | -$90.5M | -$52.8M |
| Capital expenditure | $48.2M | $46.3M | $33.9M | $40.4M | $29.8M |
| Total debt | $726M | $731M | $737M | $130M | $131M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| iRhythm IRTC | $3.19B | -19% | +22% | 5% | 99.8× | 46.9% |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
| Boston Scientific BSX | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% |
| GE HealthCare GEHC | $37.8B | +30% | +7% | 14% | 15.6× | 5.0% |
| Koninklijke Philips PHIA.AS | $29.0B | +17% | -1% | 10% | 16.4× | 5.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IRTC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.7% | -3.4% | 4th lowest of 21 |
| 6-month return | -18.9% | +3.2% | 5th lowest of 21 |
| Distance from 52-week high | -50.7% | -27.7% | 3rd lowest of 21 |
| Revenue growth (TTM) | +21.6% | +4.7% | 5th highest of 20 |
| Operating margin | 4.9% | 9.9% | 7th lowest of 19 |
| Forward P/E | 99.8× | 24.4× | 2nd most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 46.9% | 11.3% | 3rd most demanding of 17 |
| Growth delivered (Del g) | +23.0% | +8.0% | 2nd highest of 17 |
| Hurdle (Req g minus delivered) | +23.9 pp | +1.2 pp | 6th most demanding of 17 |
| ROIC minus cost of capital | -0.9 pp | -1.2 pp | 8th highest of 18 |
| EV / EBITDA | 48.8× | 16.3× | 2nd most expensive of 11 |
| Net debt / EBITDA | 2.3× | 0.2× | 3rd most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| iRhythm IRTC | United States | $3.19B | -19% | +22% | 5% | 99.8× | 46.9% | +23.0% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.20B | -13% | -1% | 13% | 24.4× | 8.7% | -4.2% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% | +10.8% |
| Zhende Medical 603301.SS | China | $3.26B | -10% | +8% | 7% | 42.5× | 22.9% | -16.1% |
| iRay Technology 688301.SS | China | $3.31B | -30% | +58% | 24% | 25.7× | n/a | n/a |
| MGI Tech 688114.SS | China | $3.06B | -4% | +2% | -7% | n/a | 43.7% | -0.1% |
| TransMedics TMDX | United States | $3.35B | +42% | +28% | 12% | 43.4× | 38.4% | +88.2% |
| Autobio Diagnostics 603658.SS | China | $3.36B | +16% | +3% | 25% | 20.3× | -0.4% | +7.2% |
| Pulse Biosciences PLSE | United States | $3.37B | +76% | +1,637% | -5,821% | n/a | n/a | n/a |
| Axogen AXGN | United States | $3.40B | +33% | +24% | -5% | 87.3× | 52.6% | +14.9% |
| Ambu A/S AMBU-B.CO | Denmark | $3.47B | +31% | +7% | 13% | 28.8× | 10.0% | +10.0% |
| Sumitomo Bakelite 4203.T | Japan | $3.50B | +7% | +15% | 13% | 15.9× | 8.6% | +8.9% |
| AtriCure ATRC | United States | $2.82B | +91% | +14% | 3% | 212.4× | 54.2% | +20.9% |
| Tecan TECN.SW | Switzerland | $3.60B | +59% | -4% | 1% | 35.5× | 45.4% | +3.8% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -1% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| COMET COTN.SW | Switzerland | $2.78B | -15% | -3% | 6% | 32.8× | n/a | n/a |
| Celcuity CELC | United States | $2.73B | -60% | n/a | n/a | n/a | n/a | n/a |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.73B | +32% | +4% | 15% | 23.0× | 12.7% | +11.0% |
| Envista NVST | United States | $3.81B | 0% | +10% | 12% | 14.7× | 4.8% | +7.1% |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $2.65B | -30% | +5% | 17% | 12.3× | -1.2% | +8.0% |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% | -7.4% |
iRhythm has 1 bond outstanding with $661M face value.